Chemistry:CVL-871
From HandWiki
Short description: Chemical compound
| Clinical data | |
|---|---|
| Routes of administration | Oral administration |
| Drug class | Dopamine receptor agonist |
CVL-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.[1][2] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] CVL-871 acts as a selective partial agonist of the dopamine D1 and D5 receptors.[1][2][3] It is taken via oral administration.[1] As of April 2022, CVL-871 is in phase 2 clinical trials for dementia-related apathy.[1]
See also
- Tavapadon (CVL-751)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "CVL 871 - AdisInsight". https://adisinsight.springer.com/drugs/800058095.
- ↑ 2.0 2.1 "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci 3 (6): 1042–1062. December 2020. doi:10.1021/acsptsci.0c00117. PMID 33344888.
- ↑ "CVL-871 - Cerevel Therapeutics". 2 January 2020. https://www.cerevel.com/compounds/cvl-871/.
External links
 |  |
